
Silvio Bellino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5532949/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. Journal of Clinical Medicine, 2016, 5, 67. | 2.4 | 123 |
| 2 | Olanzapine augmentation of fluvoxamine-refractory obsessive–compulsive disorder (OCD): a 12-week open trial. Psychiatry Research, 2000, 96, 91-98. | 3.3 | 110 |
| 3 | The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91. | 10.4 | 96 |
| 4 | Dysmorphic concern symptoms and personality disorders: A clinical investigation in patients seeking cosmetic surgery. Psychiatry Research, 2006, 144, 73-78. | 3.3 | 80 |
| 5 | Clinical picture of obsessive-compulsive disorder with poor insight: A regression model. Psychiatry Research, 2005, 136, 223-231. | 3.3 | 75 |
| 6 | Depressive and negative symptoms in schizophrenia: different effects on clinical features. Comprehensive Psychiatry, 2005, 46, 304-310. | 3.1 | 65 |
| 7 | Combined Treatment of Major Depression in Patients with Borderline Personality Disorder: A Comparison with Pharmacotherapy. Canadian Journal of Psychiatry, 2006, 51, 453-460. | 1.9 | 63 |
| 8 | Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review. Frontiers in Psychiatry, 2019, 10, 67. | 2.6 | 60 |
| 9 | Discontinuation Syndrome in Dysthymic Patients Treated with Selective Serotonin Reuptake Inhibitors. CNS Drugs, 2002, 16, 273-283. | 5.9 | 59 |
| 10 | Efficacy and Tolerability of Quetiapine in the Treatment of Borderline Personality Disorder. Journal of Clinical Psychiatry, 2006, 67, 1042-1046. | 2.2 | 50 |
| 11 | Adaptation of Interpersonal Psychotherapy to Borderline Personality Disorder: A Comparison of Combined Therapy and Single Pharmacotherapy. Canadian Journal of Psychiatry, 2010, 55, 74-81. | 1.9 | 45 |
| 12 | Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid. Journal of Psychopharmacology, 2014, 28, 125-132. | 4.0 | 45 |
| 13 | Relationships of Age at Onset With Clinical Features and Cognitive Functions in a Sample of Schizophrenia Patients. Journal of Clinical Psychiatry, 2004, 65, 908-914. | 2.2 | 44 |
| 14 | Efficacy and Tolerability of Pharmacotherapies for Borderline Personality Disorder. CNS Drugs, 2008, 22, 671-692. | 5.9 | 42 |
| 15 | Oxcarbazepine in the Treatment of Borderline Personality Disorder. Journal of Clinical Psychiatry, 2005, 66, 1111-1115. | 2.2 | 41 |
| 16 | Major Depression in Patients with Borderline Personality Disorder: A Clinical Investigation. Canadian Journal of Psychiatry, 2005, 50, 234-238. | 1.9 | 37 |
| 17 | Quality of Life of Patients Who Undergo Breast Reconstruction after Mastectomy: Effects of Personality Characteristics. Plastic and Reconstructive Surgery, 2011, 127, 10-17. | 1.4 | 37 |
| 18 | Early Detection and Outcome in Borderline Personality Disorder. Frontiers in Psychiatry, 2019, 10, 710. | 2.6 | 37 |

SILVIO BELLINO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Combined Therapy of Major Depression with Concomitant Borderline Personality Disorder: Comparison of Interpersonal and Cognitive Psychotherapy. Canadian Journal of Psychiatry, 2007, 52, 718-725. | 1.9 | 34 |
| 20 | Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?. International Journal of Molecular Sciences, 2019, 20, 5257. | 4.1 | 33 |
| 21 | Pharmacotherapy of Borderline Personality Disorder: A Systematic Review. Current Medicinal Chemistry, 2011, 18, 3322-3329. | 2.4 | 25 |
| 22 | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. Journal of Psychopharmacology, 2010, 24, 333-339. | 4.0 | 24 |
| 23 | Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?. Expert Opinion on Pharmacotherapy, 2020, 21, 47-61. | 1.8 | 24 |
| 24 | Borderline Personality Disorder: Risk Factors and Early Detection. Diagnostics, 2021, 11, 2142. | 2.6 | 23 |
| 25 | Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: A two-years follow-up. Psychiatry Research, 2016, 240, 151-156. | 3.3 | 21 |
| 26 | Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 2767-2779. | 2.2 | 21 |
| 27 | The Role of Trauma in Early Onset Borderline Personality Disorder: A Biopsychosocial Perspective. Frontiers in Psychiatry, 2021, 12, 721361. | 2.6 | 21 |
| 28 | No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. Psychiatry Investigation, 2013, 10, 180. | 1.6 | 20 |
| 29 | Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. Molecular Diagnosis and Therapy, 2014, 18, 567-577. | 3.8 | 19 |
| 30 | Unblending Borderline Personality and Bipolar Disorders. Journal of Psychiatric Research, 2017, 91, 90-97. | 3.1 | 19 |
| 31 | Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial. CNS Drugs, 2017, 31, 809-819. | 5.9 | 19 |
| 32 | Autobiographical memories, identity disturbance and brain functioning in patients with borderline personality disorder: An fMRI study. Heliyon, 2019, 5, e01323. | 3.2 | 19 |
| 33 | The Impact of SARS-CoV-2 Infection on Youth Mental Health: A Narrative Review. Biomedicines, 2022, 10, 772. | 3.2 | 19 |
| 34 | Combination of Omega-3 Fatty Acids and Valproic Acid in Treatment of Borderline Personality Disorder: A Follow-Up Study. Clinical Drug Investigation, 2018, 38, 367-372. | 2.2 | 18 |
| 35 | Accuracy of self-assessment of real-life functioning in schizophrenia. NPJ Schizophrenia, 2021, 7, 11. | 3.6 | 18 |
| 36 | Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: Predictors of response. Psychiatry Research, 2015, 226, 284-288. | 3.3 | 16 |

SILVIO BELLINO

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Long Term Treatment of Obsessive-Compulsive Disorder. CNS Drugs, 1998, 10, 247-255. | 5.9 | 15 |
| 38 | Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Research, 2008, 161, 206-212. | 3.3 | 15 |
| 39 | Models Predicting Psychosis in Patients With High Clinical Risk: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 223. | 2.6 | 15 |
| 40 | Paliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability. Depression Research and Treatment, 2011, 2011, 1-7. | 1.3 | 12 |
| 41 | Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology. International Journal of Molecular Sciences, 2020, 21, 6042. | 4.1 | 12 |
| 42 | Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial. Clinical Drug Investigation, 2019, 39, 169-178. | 2.2 | 11 |
| 43 | Trauma and psychopathology associated with early onset BPD: an empirical contribution. Journal of Psychiatric Research, 2020, 131, 54-59. | 3.1 | 11 |
| 44 | Mental Health in Childhood and Adolescence: The Role of Polyunsaturated Fatty Acids. Biomedicines, 2021, 9, 850. | 3.2 | 11 |
| 45 | Type I and type II schizophrenia: relations between tonic electrodermal activity and clinical ratings before and after haloperidol treatment. Psychiatry Research, 1995, 57, 49-56. | 3.3 | 9 |
| 46 | An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly. Current Therapeutic Research, 1997, 58, 798-808. | 1.2 | 9 |
| 47 | Recognition and Treatment of Dysthymia in Elderly Patients. Drugs and Aging, 2000, 16, 107-121. | 2.7 | 9 |
| 48 | Treating Depression: What Patients Want; Findings From a Randomized Controlled Trial in Primary Care. Psychosomatics, 2016, 57, 616-623. | 2.5 | 9 |
| 49 | Primary Psychosis: Risk and Protective Factors and Early Detection of the Onset. Diagnostics, 2021, 11, 2146. | 2.6 | 8 |
| 50 | Clinical features of dysthymia and age: a clinical investigation. Psychiatry Research, 2001, 103, 219-228. | 3.3 | 7 |
| 51 | Recent approaches to pharmacotherapy of personality disorders. Neuropsychiatry, 2011, 1, 259-273. | 0.4 | 6 |
| 52 | Interpersonal Psychotherapy Adapted for Borderline Personality Disorder (IPT-BPD): A Review of Available Data and a Proposal of Revision. , 2015, 05, . | | 5 |
| 53 | The Italian Version of the Borderline Personality Disorder Severity Index IV: Psychometric Properties, Clinical Usefulness, and Possible Diagnostic Implications. Journal of Personality Disorders, 2018, 32, 207-219. | 1.4 | 5 |
| 54 | Effectiveness of psychosocial treatments on symptoms and functional domains in schizophrenia spectrum disorders: a prospective study in a real-world setting. Disability and Rehabilitation, 2019, 41, 2799-2806. | 1.8 | 5 |

SILVIO BELLINO

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Efficacy of Polyunsaturated Fatty Acids (PUFAs) on Impulsive Behaviours and Aggressiveness in Psychiatric Disorders. International Journal of Molecular Sciences, 2021, 22, 620. | 4.1 | 5 |
| 56 | How Interpersonal Psychotherapy Changes the Brain. Journal of Clinical Psychiatry, 2021, 83, . | 2.2 | 5 |
| 57 | Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders. Current Psychopharmacology, 2012, 2, 5-17. | 0.3 | 4 |
| 58 | Pharmacotherapy of personality disorders: what we know and what we have to search for. Future Neurology, 2017, 12, 199-222. | 0.5 | 4 |
| 59 | Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54. | 2.6 | 4 |
| 60 | Interpersonal Psychotherapy as a Single Treatment for Borderline Personality Disorder: A Pilot Randomized-Controlled Study. Frontiers in Psychiatry, 2020, 11, 578910. | 2.6 | 3 |
| 61 | Pharmacological Treatment for Social Cognition: Current Evidence. International Journal of Molecular Sciences, 2021, 22, 7457. | 4.1 | 3 |
| 62 | New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder. Current Psychopharmacology, 2012, 1, 86-96. | 0.3 | 1 |
| 63 | Treatment-induced brain plasticity in borderline personality disorder: review of functional MRI studies. Future Neurology, 2018, 13, 225-238. | 0.5 | 1 |
| 64 | Editorial: Psychosis and Personality Disorders: Do We Need Early Diagnosis for Successful Treatment?. Frontiers in Psychiatry, 2020, 11, 584. | 2.6 | 0 |
| 65 | Editorial: Borderline Personality Disorders in Adolescents: Clinical Challenges and Recent Advances. Frontiers in Psychiatry, 2022, 13, 854833. | 2.6 | 0 |
| 66 | The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia. NPJ Schizophrenia, 2022, 8, 18. | 3.6 | 0 |